Patents Examined by Michael G. Hartley
  • Patent number: 10668174
    Abstract: A method of reducing radiation exposure of a non-cancerous tissue of a patient diagnosed with a cancer includes administering to the patient an agent capable of competing for binding sites on a surface of the non-cancerous tissue, provided that the administration is carried out after a waiting period that follows administration of a compound including a radionuclide to the patient, the compound having affinity for both a cancerous tissue and the non-cancerous tissue, and, further provided that the binding sites have an affinity for both the agent and the compound.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: June 2, 2020
    Assignee: Molecular Insight Pharmaceuticals, Inc.
    Inventors: John W. Babich, Shawn Hillier, John Joyal
  • Patent number: 10668126
    Abstract: The present invention relates to pharmaceutical compositions for treating neoplasias in an animal or human comprised of a carrier and therapeutically effective amounts of at least one chemotherapeutic agent along with the biotherapeutic endogenous pentapeptide Met-enkephalin, referred to as opioid growth factor. Also provided are methods of treating neoplasias in an animal or human in need of such treatment, comprising the administration to the animal or human therapeutically effective amounts of a pharmaceutical composition comprised of a carrier and therapeutically effective amounts of at least one neoplasia-treating agent, such as a chemotherapeutic agent or radiation, along with opioid growth factor.
    Type: Grant
    Filed: February 21, 2005
    Date of Patent: June 2, 2020
    Assignee: The Penn State University Research Foundation
    Inventors: Ian S. Zagon, Patricia J. McLaughlin, Jill P. Smith
  • Patent number: 10670581
    Abstract: The present invention provides oxygenized nanobubbles and their uses in imaging and cancer treatment when combined with therapeutic drugs and precise ultrasound beam steering.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: June 2, 2020
    Assignee: Purdue Research Foundation
    Inventors: Joseph Irudayaraj, Pushpak Bhandari
  • Patent number: 10660835
    Abstract: A method directed to a hair soaking treatment for frizz reduction comprising immersion of consumer hair into an aqueous composition is disclosed. A method for hair frizz reduction wherein hair is soaked for at least about 2 minutes in an aqueous composition having a viscosity of less than about 1000 cP comprising from about 0.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: May 26, 2020
    Assignee: The Procter and Gamble Company
    Inventors: Supriya Punyani, Jennifer Mary Marsh, James Charles Dunbar, Curtis Bobby Motley, Lisa Jo Bartz, Erica Vencil Buckner
  • Patent number: 10660976
    Abstract: Among the various aspects of the present disclosure is the provision of compositions and methods for imaging and treating subjects with amyloidosis or multiple myeloma with or without amyloidosis.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: May 26, 2020
    Assignee: Washington University
    Inventor: Vijay Sharma
  • Patent number: 10660974
    Abstract: Dioxetane-based chemiluminescence probes, more specifically fluorophore-tethered dioxetane-based chemiluminescence probes and ?* acceptor group-containing dioxetane based chemiluminescence probes can be included in compositions. The chemiluminescence probes are useful for both diagnostics and in vivo imaging.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: May 26, 2020
    Inventors: Doron Shabat, Ronit Satchi-Fainaro, Nir Hananya, Ori Green, Tal Eilon
  • Patent number: 10653805
    Abstract: This document relates to compounds useful for targeting PARP1. Also provided herein are methods for using such compounds to detect and image cancer cells.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: May 19, 2020
    Assignee: The General Hospital Corporation
    Inventors: Thomas Reiner, Edmund J. Keliher, Ralph Weissleder
  • Patent number: 10656152
    Abstract: A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: May 19, 2020
    Assignee: ForSight Vision4, Inc.
    Inventors: Eugene de Juan, Jr., Yair Alster, Steven M. Chamow, Kathleen C. Farinas, Hanson S. Gifford, III, K. Angela Macfarlane, Cary J. Reich, Michael Barrett, Randolph E. Campbell, Robert George, Douglas Sutton
  • Patent number: 10646592
    Abstract: This invention relates to, in part, methods and compositions that are useful for the diagnosis, treatment, or prevention of a blinding eye disease, including in the discovery of drugs that are efficacious against these diseases. Diseases include, for example, age related macular degeneration and reticular pseudodrusen disease, and the methods described herein include, for example, the method named delayed near infrared analysis (DNIRA).
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: May 12, 2020
    Assignee: Translatum Medicus Inc.
    Inventor: Shelley Romayne Boyd
  • Patent number: 10646596
    Abstract: A novel near-infrared dye-bound transferrin exhibiting a high absorption coefficient in the near-infrared wavelength region, a high tumor accumulation property, a high tumor/blood ratio and a high imaging contrast, and a contrast agent for photoacoustic imaging, including the same are provided. A compound is provided in which transferrin and an organic dye having a specified structure that absorbs light in the near-infrared wavelength region are covalently bound.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: May 12, 2020
    Inventors: Fumio Yamauchi, Kengo Kanazaki, Satoshi Ogawa
  • Patent number: 10646595
    Abstract: Water soluble porphyrin compounds useful in the field of magnetic resonance imaging (MRI) as contrast agents. Particular compounds include manganese.
    Type: Grant
    Filed: February 12, 2013
    Date of Patent: May 12, 2020
    Inventors: Xiao-an Zhang, Wei Ran Cheng, Inga Haedicke, Hai-Ling Cheng
  • Patent number: 10640457
    Abstract: The invention provides for a method for screening compounds that bind to and modulate a histone acetyltransferase protein. The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a HAT-activating compound to a subject.
    Type: Grant
    Filed: June 11, 2012
    Date of Patent: May 5, 2020
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Yan Feng, Mauro Fa, Ottavio Arancio, Shixian Deng, Donald W. Landry, Yitshak Francis
  • Patent number: 10639269
    Abstract: Cosmetic compositions are provided that include an extract from a seed of the Nicotiana species, one or more cosmetically acceptable carriers to act as a diluent, dispersant or carrier for the composition, and optionally one or more cosmetic adjuvants. The tobacco seed extract is typically characterized as having a significant lipid content and, thus, finds use as an oil component in a cosmetic composition.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: May 5, 2020
    Assignee: R.J. Reynolds Tobacco Company
    Inventors: Anthony Richard Gerardi, Barry Smith Fagg, Thaddeus Jude Jackson
  • Patent number: 10632078
    Abstract: The present invention relates to an improved gelatinous coated dosage form having two end regions coated with gelatinous materials and an exposed circumferential band. Openings are provided in at least the exposed band to reveal the core material. The invention also relates to methods for manufacturing such gelatinous coated dosage forms.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: April 28, 2020
    Inventors: Roger A Rinker, Nicholas J. Casale, James H. Comly, Brenda Pollock, Johan Geerke, Martin Costello, Dennis Wieand, Kishor Parekh
  • Patent number: 10633404
    Abstract: This disclosure relates to compositions comprising substituted iminodiacetic acid ligands and metal tricarbonyl complexes containing the ligands and derivatives thereof. In certain embodiments, the metal tricarbonyl complexes are used as radioisotope tracers such as renal tracers. In certain embodiments, the metal complexes comprise 99mTc or Re. In certain embodiments, the ligands are substituted with a fluorine, a fluorine-18 (F18) radioisotope, or other radionuclide.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: April 28, 2020
    Assignee: Emory University
    Inventors: Jeffrey Klenc, Malgorzata Lipowska, Andrew Taylor
  • Patent number: 10636536
    Abstract: The present disclosure relates to systems and methods for producing tailored solutions or medicaments containing radioactive isotopes (e.g., alpha particle emitting radioactive isotopes). The solutions may be produced by appropriate aging and separation steps. Therapeutically effective amounts of Pb-212 and/or Bi-213 may thus be obtained.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: April 28, 2020
    Assignee: RADTRAN LLC
    Inventor: Saleem S. Drera
  • Patent number: 10620215
    Abstract: The present invention relates to a fluorescence sensor capable of real-time imaging for measuring a cellular thiol level. The present invention reveals that the fluorescence intensity of the fluorescent real-time SH group-tracer (FreSH-Tracer) of the present invention increases or decreases continuously, ratiometrically or reversibly depending on the thiol level in living cells, and thus can be usefully used as a biosensor which is remarkably susceptible to quantitative or qualitative real-time detection of the cellular thiol level in living cells.
    Type: Grant
    Filed: January 2, 2019
    Date of Patent: April 14, 2020
    Assignees: Cell2In, Inc., Korea University Reserach and Business Foundation, SNU R&DB Foundation
    Inventors: In-Gyu Kim, Ki Hang Choi, Eui Man Jeong, Heun Soo Kang
  • Patent number: 10610607
    Abstract: The present invention provides a magnetic graphene-like nanoparticle or graphitic nano- or microparticle. The magnetic graphene-like nanoparticle or graphitic nano- or microparticle of the invention exhibits a high relaxivity, and is useful as a MRI contrast agent. The present invention also provides a composition for use with MRI imaging, comprising a sufficient amount of the magnetic graphene-like nanoparticles or graphitic nano- or microparticles and one or more physiologically acceptable carriers or excipients. The present invention also provides methods of using the magnetic graphene-like nanoparticles or graphitic nano- or microparticles as MRI contrast agents. The present invention further provides methods of producing the magnetic graphene-like nanoparticle or graphitic nano- or microparticle.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: April 7, 2020
    Assignee: The Research Foundation for The State University of New York
    Inventors: Balaji Sitharaman, Bhavna S. Paratala
  • Patent number: 10604516
    Abstract: The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof. wherein: R1 and R2 are each separately selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R3 is hydrogen or halogen; ring A is a benzene ring or a pyridine ring; ring B is selected from the group consisting of the following formulas (i), (ii), (iii), and (iv): in the formula (ii), Ra is alkyl; R4 and R5 are each separately selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl; and ??[Formula 3] represents a double bond or a triple bond. The above compound can be used as a molecular probe for imaging tau proteins that accumulate in the brain.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: March 31, 2020
    Assignee: National Institutes for Quantum and Radiological Science and Technology
    Inventors: Makoto Higuchi, Tetsuya Suhara, Masahiro Maruyama, Meiei Cho, Hitoshi Shimada
  • Patent number: 10604523
    Abstract: The present invention relates to novel 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]-quinoxaline derivatives as inhibitors of phosphodiesterase 2 (PDE2) and to a lesser extent of phosphodiesterase 10 (PDE10) or as inhibitors of both, phosphodiesterases 2 and 10. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which PDE2 is involved, or disorders in which both PDE2 and PDE10 are involved, such as neurological and psychiatric disorders, and endocrinological or metabolic diseases. The present invention also relates to radiolabelled compounds which may be useful for imaging and quantifying the PDE2 enzyme in tissues, using positron-emission tomography (PET).
    Type: Grant
    Filed: June 26, 2012
    Date of Patent: March 31, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: José Ignacio Andrés-Gil, Peter Jacobus Johannes Antonius Buijnsters, Andrés Avelino Trabanco-Suárez, Meri De Angelis, Greta Constantia Peter Vanhoof, Jérôme Emile Georges Guillemont, Frederik Jan Rita Rombouts, Maarten Vliegen, Guy Maurits R. Bormans, Sofie Jeanne Leopoldine Celen